Muzaffar H. Qazilbash

Muzaffar H. Qazilbash

Auto-generated profile, based on publicly available information

Muzaffar H. Qazilbash

Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PKPartow Kebriaei
Partow Kebriaei
HSHarjeet Singh
Harjeet Singh
MHM. Helen Huls
M. Helen Huls
MFMatthew J. Figliola
Matthew J. Figliola
RBRoland Bassett
Roland Bassett
LCLaurence J.N. Cooper
Laurence J.N. Cooper
BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs) improve outcomes for CD19-expressing B cell malignancies. We evaluated a human application of T cells that were genetically modified using the Sleeping Beauty (SB) transposon/transposase system to express a CD19-specific CAR. METHODS. T cells were genetically modified using DNA plasmids from the SB platform to stably express a second-generation CD19-specific CAR and selectively propagated ex vivo with activating and propagating cells (AaPCs) and cytokines. Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia safely underwent hematopoietic stem cell transplantation (HSCT) and infusion of CAR T cells as adjuvant therapy in the autologous (n = 7) or allogeneic settings (n = 19). RESULTS. SB-mediated genetic transposition and stimulation resulted in 2,200- to 2,500-fold ex vivo expansion of genetically modified T cells, with 84% CAR expression, and without integration hotspots. Following autologous HSCT, the 30-month progression-free and overall survivals were 83% and 100%, respectively. After allogeneic HSCT, the respective 12-month rates were 53% and 63%. No acute or late toxicities and no exacerbation of graft-versus-host disease were observed. Despite a low antigen burden and unsupportive recipient cytokine environment, CAR T cells persisted for an average of 201 days for autologous recipients and 51 days for allogeneic recipients. CONCLUSIONS. CD19-specific CAR T cells generated with SB and AaPC platforms were safe, and may provide additional cancer control as planned infusions after HSCT. These results support further clinical development of this nonviral gene therapy approach. TRIAL REGISTRATION. Autologous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT01492036. FUNDING. National Cancer Institute, private foundations, and institutional funds. Please see Acknowledgments for details.

22 September 2016 in Leukemia
Verified
Journal Article
Open access
PDF file
MQM H Qazilbash
M H Qazilbash
EWE Wieder
E Wieder
PTP F Thall
P F Thall
XWX Wang
X Wang
RRR Rios
R Rios
JMJ J Molldrem
J J Molldrem
PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTLs) that preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety, immunogenicity and clinical activity of PR1 vaccination, a phase I/II trial was conducted. Sixty-six HLA-A2+ patients with acute myeloid leukemia (AML: 42), chronic myeloid leukemia (CML: 13) or myelodysplastic syndrome (MDS: 11) received three to six PR1 peptide vaccinations, administered subcutaneously every 3 weeks at dose levels of 0.25, 0.5 or 1.0 mg. Patients were randomized to the three dose levels after establishing the safety of the highest dose level. Primary end points were safety and immune response, assessed by doubling of PR1/HLA-A2 tetramer-specific CTL, and the secondary end point was clinical response. Immune responses were noted in 35 of 66 (53%) patients. Of the 53 evaluable patients with active disease, 12 (24%) had objective clinical responses (complete: 8; partial: 1 and hematological improvement: 3). PR1-specific immune response was seen in 9 of 25 clinical responders versus 3 of 28 clinical non-responders (P=0.03). In conclusion, PR1 peptide vaccine induces specific immunity that correlates with clinical responses, including molecular remission, in AML, CML and MDS patients.

1 July 2009 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
GPGaurav C. Parikh
Gaurav C. Parikh
AAAli Imran Amjad
Ali Imran Amjad
RSRima M. Saliba
Rima M. Saliba
SKSyed M.A. Kazmi
Syed M.A. Kazmi
ZKZiad U. Khan
Ziad U. Khan
MQMuzaffar H. Qazilbash
Muzaffar H. Qazilbash
Approximately 20% of patients with multiple myeloma (MM) have renal failure at diagnosis, and about 5% are dialysis-dependent. Many of these patients are considered ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) because of a high risk of treatment-related toxicity. We evaluated the outcome of 46 patient with MM and renal failure, defined as serum creatinine >2 mg/dL sustained for >1 month before the start of preparative regimen. Patients received auto-HSCT at our institution between September 1997 and September 2006. Median serum creatinine and creatinine clearance (CrCl) at auto-HSCT were 2.9 mg/dL (range: 2.0-12.5) and 33 mL/min (range: 8.7-63), respectively. Ten patients (21%) were dialysis-dependent. Median follow-up in surviving patients was 34 months (range: 5-81). Complete (CR) and partial responses (PR) after auto-HSCT were seen in 9 (22%) and 22 (53%) of the 41 evaluable patients, with an overall response rate of 75%. Two patients (4%) died within 100 days of auto-HSCT. Grade 2-4 nonhematologic adverse events were seen in 18 patients (39%) and included cardiac arrythmias, pulmonary edema, and hyperbilirubinemia. Significant improvement in renal function, defined as an increase in flomerular filtration rate (GFR) by 25% above baseline, was seen in 15 patients (32%). Kaplan-Meier estimates of 3-year progression-free survival (PFS) and overall survival (OS) were 36% and 64%, respectively. In conclusion, auto HSCT can be offered to patients with MM and renal failure with acceptable toxicity and with a significant improvement in renal function in approximately one-third of the transplanted patients. In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM).

23 September 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
PMPashna N. Munshi
Pashna N. Munshi
DVDavid Vesole
David Vesole
AJArtur Jurczyszyn
Artur Jurczyszyn
JZJan Maciej Zaucha
Jan Maciej Zaucha
AMAndrew St. Martin
Andrew St. Martin
ADAnita D’sOuza
Anita D’sOuza

2 February 2006 in Cancer
Verified
Journal Article
Closed access
PDF file
MQMuzaffar H. Qazilbash
Muzaffar H. Qazilbash
RSRima Saliba
Rima Saliba
MLMarcos De Lima
Marcos De Lima
CHChitra Hosing
Chitra Hosing
DCDaniel Couriel
Daniel Couriel
SGSergio A. Giralt
Sergio A. Giralt

24 August 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
QBQaiser Bashir
Qaiser Bashir
NSNina Shah
Nina Shah
SPSimrit Parmar
Simrit Parmar
WWWei Wei
Wei Wei
GRGabriela Rondon
Gabriela Rondon
MQMuzaffar H. Qazilbash
Muzaffar H. Qazilbash
We retrospectively analyzed the outcomes of all consecutive patients with myeloma (n = 84) aged ≥70 years who had received autologous hematopoietic stem cell transplant (auto HCT) between July 1999 and June 2010 at our institution. The median age at auto HCT was 72 years, the median number of prior therapies was 2.5 and the median time from diagnosis to auto HCT was 10.2 months. The conditioning regimen consisted of melphalan at 140 mg/m2 in 10%, 180 mg/m2 in 25% and 200 mg/m2 in 65% of patients. The day-100 non-relapse mortality was 3%. The overall response rate at day 100 was 85% (complete response 18%, very good partial response 12%, partial response 55%). After a median follow-up of 25 months among surviving patients, the estimated progression-free survival and overall survival at 5 years were 27% and 67%, respectively. The incidence of grade II–IV toxicity, response rate and survival were similar across three melphalan dose levels. These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT.